Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

BACKGROUND: The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS patients in France reported ADR due to first-line disease-modifying drugs...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Trials
Auteurs principaux: Defer, Gilles, Le Caignec, Florian, Fedrizzi, Sophie, Montastruc, François, Chevanne, Damien, Parienti, Jean-Jacques, Peyro-Saint-Paul, Laure
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845183/
https://ncbi.nlm.nih.gov/pubmed/29523169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2560-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires